Outcome for Board Meeting held today for approving Audited Financials and Recommending Final Dividend.
MEDANTA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Global Health Limited (Medanta) reported strong full-year FY2026 consolidated results. Total income grew to ₹45,088.60 million from ₹37,712.92 million in FY2025, representing approximately 19.4% year-on-year revenue growth. Profit after tax (PAT) stood at ₹5,540.68 million versus ₹4,813.18 million in the prior year, a growth of about 15%. The company recorded exceptional items of ₹10.21 million net (including ₹365.98 million impact from new Labour Codes, partially offset by EPCG reversal of ₹195.92 million and stamp duty reversal of ₹159.85 million). The statutory auditors Walker Chandiok & Co LLP issued an unmodified opinion with no audit qualifications. The Board recommended a final dividend of ₹0.50 per equity share (25% on face value of ₹2). Additionally, the company announced a new 400-bed multi-specialty hospital in Varanasi and a Business Transfer Agreement for a 79-bed oncology hospital in Indore.
The company delivered ~20% revenue growth with healthy profitability expansion. Clean audit opinion and dividend declaration are positive signals for shareholders. New hospital expansions signal growth focus.